Iris Dorbian
Agenus has completed its acquisition of 4-Antibody AG. The transaction, which consisted of Agenus buying all outstanding stock of 4-Antibody for approximately 3.3 million shares of Agenus common stock, could surpass $40 million. Also, Dr. Shahzad Malik, general partner at Advent Venture Partners, will join Agenus’ board of directors after the deal closes. Based in Europe, 4-Antibody AG, which is backed by Advent Venture Partners, is a biopharmaceutical company. Agenus is backed by Iroquois Capital, Downsview Capital and Hudson Capital.
Principia Biopharma said Thursday that it has named Christopher Y. Chai as chief financial officer and Dr. Steven G. Gourlay as chief medical officer. Previously, Chai worked at MAP Pharmaceuticals where he served as senior vice president and CFO while Gourlay was a partner at GBS Venture Partners. Based in South San Francisco, Principia Biopharma is a pre-clinical stage company focused on immunology, autoimmune diseases and oncology. Its backers include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.
BlueConic has closed $3 million in Series A funding. Sigma Prime Ventures led the round. Based in Boston, BlueConic is a customer engagement platform.
According to a blog post on its site, MyHealthTeams has closed $3.36 million in Series A financing. Westly Group led the round with participation from Adams Street Partners, 500 Startups, HealthTechCapital, Sand Hill Angels and TEEC. In conjunction with the funding, Westly Group's Gary Dillabough will join the board of directors. Based in San Francisco, MyHealthTeams builds social networks for people facing chronic health conditions. To read more about the funding, visit here.
Oorja said Wednesday that it has secured Series E funding. No financial terms were disclosed. The investors included Mingxin China Growth Fund and DAG Ventures. Headquartered in Fremont, Calif., Oorja is a provider of liquid fuel cell technology for the material handling and telecommunication tower sectors.
ARCA biopharma has appointed Dan Mitchell to its board of directors. Mitchell is a manager of Sequel Venture Partners, which he founded. Based in Colorado, ARCA is a biopharmaceutical company focused on cardiovascular diseases.
VoAPPs said Wednesday that it has closed $1.5 million in Series B funding. The investors included Buckhead Investment Partners Early Stage Fund, Bert Ellis and Paul Iaffaldano. In addition to the funding, VoAPPs has named Mark Buffington, co-founder of Buckhead Investment Partners, to its board of directors. Based in Atlanta, VoAPPs is a developer of voice apps.
Lithera has raised $8 million in the final close of its Series C round, bringing the tally to $35.6 million. The investors include Alta Partners, Domain Associates, AKS Capital and several unnamed backers. Based in San Diego, Calif., Lithera is a maker of products for aesthetic medicine.
IZEA has agreed to sell approximately 34.2 million shares of its stock at a price of $.35 per share in a $12 million private placement. Special Situations Funds led the round. Headquartered in Orlando, Florida, IZEA is a provider of social media sponsorship. Its backers include Inflexion Partners, DFJ and Village Ventures.
Flexion Therapeutics debuted its IPO after having priced its offering of 5 million shares at $13 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "FLXN." BMO Capital Markets and Wells Fargo Securities are the lead underwriters. Based in Burlington, Mass., Flexion is a pharmeceutical company developing treatments for musculoskeletal disorders. Its backers include Versant Ventures, Sofinnova Capital, Pfizer, 5AM Ventures and Novo.